Skip to main content
Clinical Trials/NCT03065114
NCT03065114
Completed
Not Applicable

Institute of Medicine, Chung Shan Medical University

Yeh0 sites500 target enrollmentDecember 1, 2014

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Genetic Disorder
Sponsor
Yeh
Enrollment
500
Primary Endpoint
implantation rate
Status
Completed
Last Updated
9 years ago

Overview

Brief Summary

Preimplantational genetic screen (PGS) is tool for diagnosis of embryo chromosome abnormality before transfer. Under this tool, patients with a family history of genetic disease or special genetic disease could avoid to produce chromosomal abnormalities of the next pregnant. This study is a retrospective study, data collection from 2001 Jan. to 2015. Nov. Patients underwent PGS and data including the couples age, infertility factors, stimulation protocols, medicine records, embryo quality records and blood tests were collected in this study. Analysis the relationship between outcomes of PGS, clinical outcomes and embryo quality is performed and further to find a diagnosis reference for clinical care.

Detailed Description

Research background Preimplantational genetic screen (PGS) is tool for diagnosis of embryo chromosome abnormality before transfer. Under this tool, patients with a family history of genetic disease or special genetic disease could avoid to produce chromosomal abnormalities of the next pregnant. For the preemergence of embryos before the genetic diagnosis must be carried out artificial reproductive treatment, the process includes induction of ovulation, ovulation, in vitro fertilization and embryo culture, to embryos grow to six to eight cells or cultured into the stage of blastocyst stage, Under the embryonic section, take one or several cells, the slices of cells for genetic diagnosis, select the embryo without genetic disease implanted in the uterine cavity, in order to avoid the birth of genetic disease offspring. PGS can reduce the pregnancy when the chromosomal abnormalities of the fetus after implantation, but also to reduce the risk of abortion from chromosomal abnormalities, and can avoid the couples implanted with genetic abnormalities of the embryos, thereby significantly reducing it is important to promote the process of eugenics and reduce the social cost. Research purposes The detection of chromosomal abnormalities of embryos are important factors for clinical diagnosis or screening before implantation. However, there is no complete analysis of domestic studies. This program will compare the genes or chromosomal abnormalities and clinical outcomes of embryo testing at different stages of embryonic development. Research design This study is a retrospective study, data collection from 2001 Jan. to 2015. Nov. Patients underwent PGS and data including the couples age, infertility factors, stimulation protocols, medicine records, embryo quality records and blood tests were collected in this study. Analysis the relationship between outcomes of PGS, clinical outcomes and embryo quality is performed and further to find a diagnosis reference for clinical care.

Registry
clinicaltrials.gov
Start Date
December 1, 2014
End Date
November 30, 2015
Last Updated
9 years ago
Study Type
Observational
Sex
Female

Investigators

Sponsor
Yeh
Responsible Party
Sponsor Investigator
Principal Investigator

Yeh

Institutional Review Board of Chung Shan Medical University

Chung Shan Medical University

Eligibility Criteria

Inclusion Criteria

  • Women underwent in vitro fertilization (IVF) treatment and preimplantational genetic screen (PGS).

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

implantation rate

Time Frame: 1~2 week after pregnancy test

detection sac after embryo transfer

Similar Trials